As we heard at the recent packed annual PING seminar that VWV held, there is no bigger issue facing the pharma industry than Brexit, and in particular the uncertainty over what will happen from a regulatory perspective.
The recent case of Pfizer Ireland Pharmaceuticals v Orifarm GmbH has resulted in an important decision of the Court of Justice of the European Union (the CJEU) on the interpretation of the Specific Mechanism.
EU citizen employees of Pharma & Life Sciences businesses concerned about their status after Brexit should know that the UK government have recently released more details about the application process they will need to go through to confirm their status.
The Italian competition regulator was right to consider a drug licensed to treat eye conditions such as glaucoma and macular degeneration (Lucentis) and another to treat tumours (Avastin) as competing, the European Court of Justice has ruled.
In August last year, Professor Sir John Bell unveiled industry-led proposals to build the UK’s status as a world leader in life sciences. The strategy was independent of the Government, so the Government was not bound by it...
The Business Secretary Greg Clark and Science Minister Sam Gyimah were there to officially cut the ribbon and open the centre to 'bridge the gap' between scientific research and commercialisation of the medicines of the future.
The European Medicines Agency has announced that it is reallocating all the regulation of EU medicines currently done by the UK's regulator, the Medicines and Healthcare products Regulatory Agency (MHRA), from Brexit on 30 March 2019.